MX2016005285A - Conjugados de somatostatina y sus analagos. - Google Patents

Conjugados de somatostatina y sus analagos.

Info

Publication number
MX2016005285A
MX2016005285A MX2016005285A MX2016005285A MX2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A MX 2016005285 A MX2016005285 A MX 2016005285A
Authority
MX
Mexico
Prior art keywords
somatostatin
conjugates
analogs
hydrogels
carriers
Prior art date
Application number
MX2016005285A
Other languages
English (en)
Inventor
V Santi Daniel
Ashley Gary
l schneider Eric
Hearn Brian
Original Assignee
Prolynx Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx Llc filed Critical Prolynx Llc
Publication of MX2016005285A publication Critical patent/MX2016005285A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describen conjugados de portadores e hidrogeles para controlar la vida media biológica de somatostatina y sus análogos.
MX2016005285A 2013-10-22 2014-10-22 Conjugados de somatostatina y sus analagos. MX2016005285A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894226P 2013-10-22 2013-10-22
PCT/US2014/061844 WO2015061503A1 (en) 2013-10-22 2014-10-22 Conjugates of somatostatin and its analogs

Publications (1)

Publication Number Publication Date
MX2016005285A true MX2016005285A (es) 2016-10-28

Family

ID=52993525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005285A MX2016005285A (es) 2013-10-22 2014-10-22 Conjugados de somatostatina y sus analagos.

Country Status (10)

Country Link
US (2) US10086049B2 (es)
EP (1) EP3060230A4 (es)
JP (1) JP2016534064A (es)
KR (1) KR20160075665A (es)
CN (1) CN106232131A (es)
AU (1) AU2014340095A1 (es)
CA (1) CA2928407A1 (es)
MX (1) MX2016005285A (es)
SG (2) SG10201803370XA (es)
WO (1) WO2015061503A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11879019B2 (en) 2016-12-19 2024-01-23 The Regents Of The University Of California Dual-enzyme responsive peptides
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN118652192A (zh) 2017-05-24 2024-09-17 德克萨斯州大学系统董事会 用于抗体药物缀合物的接头
JP6984923B2 (ja) * 2017-09-19 2021-12-22 イミュンワーク インク.Immunwork Inc. アルブミンとの強化された結合親和性を有する医薬構築物
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
CA3153644A1 (en) * 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
US20230098031A1 (en) * 2019-12-11 2023-03-30 The General Hospital Corporation Methods for cell imaging
CN114409736B (zh) * 2022-01-28 2023-09-15 中国科学院精密测量科学与技术创新研究院 一种基于两亲性寡肽的定相排列介质及其制备方法和应用
KR102835630B1 (ko) * 2022-02-25 2025-07-22 앱티스 주식회사 신규 항체 약물 접합체
US20240123095A1 (en) * 2022-09-26 2024-04-18 Boston Scientific Scimed, Inc. Crosslinked radiopaque networks for medical applications

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214792B1 (en) * 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
EP2455072A1 (en) 2005-03-11 2012-05-23 Endo Pharmaceuticals Solutions Inc. Controlled release formulations of octreotide
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
UA104866C2 (uk) 2008-06-25 2014-03-25 Ендо Фармас'Ютікалз Солюшнз Інк. Імплантат октреотиду, який містить вивільняючу речовину
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8640315B1 (en) 2009-10-28 2014-02-04 Robert E. Nikkel Rotating adapter assembly
MX343112B (es) * 2010-01-13 2016-10-25 Ipsen Pharma Sas Proceso para la preparacion de composiciones farmaceuticas para la liberacion sostenida de analogos de somatostanina.
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
KR102109067B1 (ko) * 2011-09-07 2020-05-13 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
US9585959B2 (en) 2011-12-05 2017-03-07 Camurus Ab Robust controlled-release formulations

Also Published As

Publication number Publication date
AU2014340095A1 (en) 2016-05-26
EP3060230A1 (en) 2016-08-31
JP2016534064A (ja) 2016-11-04
US10413594B2 (en) 2019-09-17
CA2928407A1 (en) 2015-04-30
WO2015061503A1 (en) 2015-04-30
EP3060230A4 (en) 2017-06-14
US20180296648A1 (en) 2018-10-18
CN106232131A (zh) 2016-12-14
SG10201803370XA (en) 2018-06-28
US20160271227A1 (en) 2016-09-22
KR20160075665A (ko) 2016-06-29
SG11201603115YA (en) 2016-05-30
US10086049B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
MX2020014120A (es) Agonistas parciales del receptor de insulina.
IN2013KO01129A (es)
MY187622A (en) Color stable red-emitting phoshors
JO3755B1 (ar) تركيبات تستوستيرون
IN2013DE00266A (es)
MX357675B (es) Anticuerpos anti-jagged y métodos de uso.
AU2014224814A8 (en) Novel halogen-substituted compounds
NZ630549A (en) N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide
MY187959A (en) Reactor
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
IN2013KO01130A (es)
GEP201706636B (en) Galactagogue compositions based on phosphatidylserine
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
IN2015KN00386A (es)
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA76716U (uk) 5,7-ДИМЕТИЛ-2-ОКСО-6-ФЕНІЛАЗО-ТІАЗОЛО[4,5-b]ПІРИДИН-3-ІЛГІДРАЗОНИ АЦЕТАТНОЇ КИСЛОТИ, ЩО ПРОЯВЛЯЮТЬ АНТИЕКСУДАТИВНУ ДІЮ
UA79072U (en) (4-tert-butylperoxy-4-methylpentyl)methacrylate
IN2013KO01440A (es)
IN2013KO01329A (es)
IN2013KO01319A (es)
UA72478U (ru) Применение полентара как средства фригопротекторного действия
UA103911U (ru) Средство с вазодилатирующей активностью
IN2012DE01204A (en) "shikhar technology"